På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

01 Sep 2017

Symphogen presents promising results from a randomized Phase 2 study with Sym004

Oral presentation of efficacy and safety data of Sym004 in refractory metastatic colorectal cancer

Symphogen today announced that the promising data from its Phase 2 study with Sym004, a mAb mixture targeting EGFR, has been selected for oral presentation on 11 September 2017 at the European Society for Medical Oncology (ESMO) 2017 Congress, taking place from 8-12 September 2017, in Madrid, Spain.

According to CEO, Martin Olin, data from the large Phase 2 study show a remarkable improvement in overall survival in a well-defined patient population suggesting that Sym004 could be a unique precision medicine opportunity for patients with late-stage metastatic colorectal cancer that otherwise have very limited or no treatment options.

Sym004 is comprised of two antibodies targeting non-overlapping epitopes on EGFR that are designed to not only block ligand induced receptor activation but also to elicit removal of EGFR from the cancer cell surface by inducing receptor internalization and degradation. Positive clinical efficacy findings for Sym004 in patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody was reported in the June 2015 issue of Cancer Discovery (Cancer Discov. 2015 Jun;5(6):598-609).

Full session details and data presentation listings for ESMO 2017 Congress can be found here

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2017 Danskbiotek. All rights reserved.